多替阿巴拉米片推荐剂量

It is a compound medicine. Each tablet contains 50 mg of dolutegravir sodium, 600 mg of abacavir sulfate, and 300 mg of lamivudine. It is suitable for treating HIV adults and patients over 12 years old. Among them, the dolutegravir component can block the strand transfer of DNA integration through binding to the integrase active site, which is one of the key steps for HIV replication, thereby inhibiting HIV integrase in the body. Dolutegravir tablets are the only three-in-one compound drug with dolutegravir (DTG) as the core. It has the characteristics of high efficacy, good tolerability, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of HIV-infected patients, thereby improving patients' medication compliance and significantly improving their quality of life.

For adults and adolescents, the recommended dose of Dolutegra is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. If the patient misses a dose of Docetaxel, and it is more than 4 hours before the next dose, Docetaxel should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group. Patients whose creatinine clearance is less than 50 mL/min are not recommended to take doptabalamid tablets. Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment and therefore its use is not recommended unless deemed necessary. For patients with mild hepatic impairment, close monitoring is required, including monitoring of abacavir plasma levels when feasible.